American Association for Cancer Research Annual Meeting

American Association for Cancer Research Annual Meeting
Name	American Association for Cancer Research Annual Meeting
Status	Active
Genre	Scientific conference
Frequency	Annual
Organized	American Association for Cancer Research
First	1907
Venue	Varies
Country	United States (primary)

Contents

American Association for Cancer Research Annual Meeting is the flagship scientific meeting of the American Association for Cancer Research, convening researchers, clinicians, policymakers, and industry representatives to present advances in oncology, tumor biology, and translational medicine. The meeting typically gathers delegates from institutions such as the National Cancer Institute, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and industry partners including Pfizer, Roche, and Merck & Co.. It is a focal point for dissemination of trials, preclinical studies, biomarker discoveries, and policy-relevant findings that influence practice at organizations like Food and Drug Administration and National Institutes of Health.

History

The Annual Meeting traces its origins to the early activities of the American Association for Cancer Research founded in 1907, and grew through interactions with entities including the American Cancer Society, Rockefeller Institute, and Beth Israel Deaconess Medical Center. During the mid-20th century the meeting intersected with major initiatives at the National Cancer Act of 1971 era and collaborations with laboratories such as Cold Spring Harbor Laboratory and Sloan Kettering Institute. In the 1990s and 2000s the meeting featured breakthroughs aligned with work at Broad Institute, Howard Hughes Medical Institute, Genentech, and consortia like The Cancer Genome Atlas and International Agency for Research on Cancer. Recent decades saw coordination with global forums including the European Society for Medical Oncology and World Health Organization convenings.

The meeting is organized under the governance structures of the American Association for Cancer Research's Board of Directors and Scientific Program Committee, with advisory input from leaders affiliated with American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Clinical Trials Transformation Initiative, and institutions such as Brigham and Women's Hospital. Leadership roles have been held by investigators from University of California, San Francisco, Stanford University, Yale University, University of Texas MD Anderson Cancer Center, and University of Pennsylvania. Funding and sponsorship involve partnerships with corporations like AstraZeneca, Bristol Myers Squibb, and philanthropic foundations such as the Bill & Melinda Gates Foundation and the V Foundation for Cancer Research.

Program tracks are structured around basic science, translational research, clinical trials, precision oncology, immuno-oncology, cancer prevention, and survivorship, drawing speakers from Cold Spring Harbor Laboratory, Salk Institute for Biological Studies, Karolinska Institute, and Imperial College London. Symposia and plenary sessions often include thematic connections to landmark efforts including CRISPR-Cas9 research, genomics initiatives like International Cancer Genome Consortium, biomarker platforms from Foundation Medicine, and regulatory perspectives connected to the European Medicines Agency. Specialized seminars and workshops feature consortiums such as NCI-MATCH, cooperative groups like SWOG Cancer Research Network, and translational hubs like Translational Genomics Research Institute.

Abstracts undergo peer review coordinated by thematic review panels with members drawn from academic centers including Columbia University, Northwestern University, University of Chicago, and research institutes such as Fred Hutchinson Cancer Research Center. The submission process uses electronic systems developed in collaboration with vendors and institutional IT groups; reviewed content spans preclinical models referencing work at Vanderbilt University Medical Center, University of Michigan, and University of California San Diego. Accepted abstracts are categorized into poster sessions, oral presentations, and rapid communications, with selection criteria informed by prior scholarship published in journals like Cancer Research, Clinical Cancer Research, Nature Medicine, The New England Journal of Medicine, and Cell.

Attendance typically includes investigators, trainees, clinicians, industry scientists, policymakers, and patient advocates from institutions including World Health Organization, European Organisation for Research and Treatment of Cancer, American Society of Hematology, and academic centers like Massachusetts General Hospital and University of Toronto. The meeting's outputs influence drug approvals at the Food and Drug Administration and European Medicines Agency and inform guideline updates by organizations such as National Comprehensive Cancer Network and American Society of Clinical Oncology. Metrics of impact include citation of abstracts in journals such as Nature, Science, and JAMA Oncology, follow-on clinical trials registered at ClinicalTrials.gov, and collaborative grants from funders like Wellcome Trust and National Institutes of Health.

Historically the meeting has showcased pivotal work including early immunotherapy data related to agents from Bristol Myers Squibb and Merck & Co., genomic revelations connected to The Cancer Genome Atlas and Broad Institute, and biomarker-driven trials allied with Foundation Medicine and Guardant Health. Distinguished awards presented or announced in association with the meeting have honored investigators affiliated with Nobel Prize laureates' institutions, recipients of the Lasker Award, and leaders recognized by the AACR-Princess Takamatsu Memorial Lectureship and AACR Award for Lifetime Achievement in Cancer Research. Keynotes and plenaries have featured speakers from National Cancer Institute, Harvard Medical School, University of Cambridge, University of Oxford, and corporate R&D heads from Novartis and Johnson & Johnson.

Category:Medical conferences